PCSK9 affects vascular senescence through the SIRT1 pathway
Experimental Gerontology · 2025
DOI: 10.1016/j.exger.2025.112701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Gerontology, 2025. Verfasst von Yuqin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Wuxi Clinical College, Anhui Medical University, Wuxi 214044, China; Department of Cardiovascular Medicine, Fi…. Hauptthemen laut MEDLINE: Sirtuin 1, Cellular Senescence, Proprotein Convertase 9, Aging. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Age is an independent risk factor for atherosclerotic cardiovascular disease that increases the susceptibility of older adults to vascular intimal thickening, endothelial dysfunction, and thrombosis. However, the mechanism underlying vascular injury is not fully understood. In the present study, the effect of proprotein convertase subtilin-type kexin 9 (PCSK9) inhibitors on the senescent state of human umbilical vein endothelial cells (HUVECs) and on senescent mice and lipopolysaccharides (LPS) were assessed. The senescent state of mice was delayed under PCSK9 inhibitor treatment, and the expression of P16, P21, and P53 proteins in senescent cells was increased because LPS induction stimulated PCSK9 activation. PCSK9 overexpression accelerated cell senescence, activated a large number of oxidative stress pathways, and increased the expression of senescence-related genes (including P16, P21, and P53). In addition, inhibition of the sirtuin 1 (SIRT)1 oxidative stress pathway can attenuate the aging-promoting effects of PCSK9, which are elevated as a result of LPS induction. The SIRT1 activator was more efficient than LPS alone in inducing the expression of senescence-related genes. Therefore, PCSK9 inhibitors can delay the aging of the vascular by reducing cellular SIRT1 levels. Therefore, it can be concluded that PCSK9 inhibition inhibits vascular senescence by reducing the expression of senescent proteins by regulating the SIRT1 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Wuxi Clinical College, Anhui Medical University, Wuxi 214044, China; Department of Cardiovascular Medicine, Fifth Clinical Medical College, Anhui Medical University, Anhui 230000,…
- Department of Cardiovascular Medicine, Fifth Clinical Medical College, Anhui Medical University, Anhui 230000, China; Department of Cardiovascular Medicine, 904th Hospital of the Joint Logistics Support Force of the Peo…
Zitieren
APA
Wang, Y., Cao, S., Wang, Z., Li, C., Ye, J., Liu, Y., Jin, T., Zhou, Y., Su, W., & Zong, G. (2025). PCSK9 affects vascular senescence through the SIRT1 pathway. Experimental Gerontology. https://doi.org/10.1016/j.exger.2025.112701
Vancouver
Wang Y, Cao S, Wang Z, Li C, Ye J, Liu Y, et al. PCSK9 affects vascular senescence through the SIRT1 pathway. Experimental Gerontology. 2025. doi:10.1016/j.exger.2025.112701
BibTeX
@article{Wang2025,
author = {Wang, Yuqin and Cao, Shaoqing and Wang, Zhangyu and Li, Chengsi and Ye, Jiangping and Liu, Yehong and Jin, Tianhui and Zhou, Yuting and Su, Wentao and Zong, Gangjun},
title = {PCSK9 affects vascular senescence through the SIRT1 pathway},
journal = {Experimental Gerontology},
year = {2025},
doi = {10.1016/j.exger.2025.112701}
}
EUVIMED